Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-04-15 9:59:54 PM | Chg. -6.37 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 898.33USD | -0.70% | 21,973 Turnover: 19.86 mill. |
-Bid Size: - | -Ask Size: - | 98.63 bill.USD | - | 24.25 |
Assets
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 527 | 974.3090 | 1,594.1200 | 2,083.4210 | 2,358.6050 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | - | 460.1540 | 632.1620 | 864.2600 | 1,486.4940 | ||||||
| Fixed Assets | - | 1,704.3660 | 2,694.0370 | 3,793.2780 | 4,429.2560 | ||||||
| Inventories | 70.4000 | 128.8610 | 238.5780 | 399.3560 | 726.1380 | ||||||
| Accounts Receivable | 891.8000 | 739.3790 | 1,152.4890 | 1,343.3680 | 1,538.6420 | ||||||
| Cash and Cash Equivalents | 535.6000 | 648.7190 | 809.1020 | 535.2030 | 812.7330 | ||||||
| Current Assets | 1,796.9000 | 2,167.4610 | 2,915.0950 | 3,180.1880 | 4,335.0300 | ||||||
| Total Assets | 2,951 | 3,871.8270 | 5,609.1320 | 6,973.4660 | 8,764.2860 | ||||||
Liabilities
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 61.9000 | - | - | - | - | ||||||
| Long-term debt | - | 146.7730 | 362.9190 | 351.5690 | 703.4530 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 998.9000 | 1,329.5020 | 1,954.2950 | 2,524.2210 | 2,620.2080 | ||||||
| Share Capital | .0990 | .1020 | .1060 | .1080 | .1100 | ||||||
| Total Equity | 1,952.1000 | 2,542.3250 | 3,654.8370 | 4,449.2450 | 6,144.0780 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,951 | 3,871.8270 | 5,609.1320 | 6,973.4660 | 8,764.2860 | ||||||
Income Statement
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 2,104.7000 | 2,819.5570 | 4,103.7280 | 4,860.4270 | 5,872.2270 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 760 | 838.4310 | 1,251.9160 | 1,330.7410 | 2,079.5910 | ||||||
| Interest Income | -46.4000 | -37.3720 | -14.2410 | -7.1950 | -25.1190 | ||||||
| Income Before Taxes | 713.4000 | 775.7470 | 1,225.0970 | 1,329.8150 | 2,078.5110 | ||||||
| Income Taxes | 289 | -427.6730 | -589.0410 | -434.2930 | -880 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 424.4000 | 348.0740 | 636.0560 | 895.5220 | 1,198.5110 | ||||||
Per Share
Cash Flow
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 583.6000 | 743.1570 | 1,330.7800 | 1,473.3960 | 1,307.1120 | ||||||
| Cash Flow from Investing Activities | -355.5000 | -420.7770 | -907.6010 | -1,046.9040 | -1,005.1820 | ||||||
| Cash Flow from Financing | 77.1000 | -209.2690 | -262.7960 | -700.3910 | -24.4000 | ||||||
| Decrease / Increase in Cash | 305.3000 | 113.1110 | 160.3830 | -273.8990 | 277.5300 | ||||||
| Employees | 2,340 | 2,925 | 4,300 | 5,400 | 6,200 | ||||||
